Striverdi Respimat

Chronic Obstructive Pulmonary Disease
Treatment
20 Active Studies for Striverdi Respimat

What is Striverdi Respimat

OlodaterolThe Generic name of this drug
Treatment SummaryOlodaterol is a medication used to treat chronic obstructive pulmonary disease (COPD). It works by activating certain receptors in the lungs that cause the airways to relax and open, making it easier to breathe. Olodaterol only needs to be taken once a day, which is more convenient than other COPD medications. It helps to reduce COPD symptoms like shortness of breath and coughing. However, it should not be used to treat asthma or sudden COPD flare-ups.
Striverdi Respimatis the brand name
Striverdi Respimat Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Striverdi Respimat
Olodaterol
2014
2

Effectiveness

How Striverdi Respimat Affects PatientsOlodaterol is a drug that helps open up the airways in the lungs. It works by binding to the beta2-adrenergic receptor, which relaxes the muscles in the lungs and makes breathing easier. Olodaterol is highly specific to this receptor and has no effect on other receptors commonly found in the heart and fat tissue. Studies have found that it can help reverse breathing difficulties caused by bronchoconstriction.
How Striverdi Respimat works in the bodyOlodaterol is a type of drug that works by widening your airways and making it easier to breathe. It binds to receptors called beta2-adrenergic receptors in the lungs which stimulate certain proteins. These proteins trigger a reaction that causes the airways to relax and open, allowing more air to flow through.

When to interrupt dosage

The recommended measure of Striverdi Respimat is dependent upon the diagnosed situation. The magnitude of dosage is contingent upon the technique of delivery outlined in the table below.
Condition
Dosage
Administration
Chronic Obstructive Pulmonary Disease
0.0025 mg, , 0.002736 mg, 0.0025 mg/pump actuation
, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution, Spray, metered, Spray, metered - Respiratory (inhalation)

Warnings

Striverdi Respimat has one contraindication. It should not be taken in the presence of any of the conditions outlined in the table below.Striverdi Respimat Contraindications
Condition
Risk Level
Notes
Asthma
Do Not Combine
There are 20 known major drug interactions with Striverdi Respimat.
Common Striverdi Respimat Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Olodaterol.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Olodaterol.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Olodaterol.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Olodaterol.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Olodaterol.
Striverdi Respimat Toxicity & Overdose RiskCommon side effects of this drug include nasal and throat irritation (11.3%), upper respiratory infection (8.2%), bronchitis (4.7%), urinary tract infection (2.5%), coughing (4.2%), dizziness (2.3%), rash (2.2%), diarrhea (2.9%), back pain (3.5%), and joint pain (2.1%).

Striverdi Respimat Novel Uses: Which Conditions Have a Clinical Trial Featuring Striverdi Respimat?

Currently, 98 trials are being conducted to investigate the potential of Striverdi Respimat to mitigate Chronic Obstructive Pulmonary Disease (COPD).
Condition
Clinical Trials
Trial Phases
Chronic Obstructive Pulmonary Disease
76 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Striverdi Respimat Reviews: What are patients saying about Striverdi Respimat?

4.3Patient Review
1/8/2016
Striverdi Respimat for Bronchospasm Prevention with COPD
I was really surprised at how quickly I noticed a difference when using this inhaler. I hadn't realized how short of breath I had been until I ran out and couldn't use it for a few days.
2Patient Review
7/4/2016
Striverdi Respimat for Bronchospasm Prevention with COPD
This treatment made me feel very dizzy and nauseous. I felt like I was going to faint.

Patient Q&A Section about striverdi respimat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a generic for Striverdi respimat?

"Striverdi is a drug used to treat chronic obstructive pulmonary disease (COPD), which is a condition that includes chronic bronchitis or emphysema. Striverdi is not as popular as other long-acting beta agonists, and there are no generic alternatives to it currently."

Answered by AI

What are the side effects of Striverdi respimat?

"This medication may increase your blood pressure. Keep track of your blood pressure readings and let your doctor know if they are higher than normal. Be sure to tell your doctor right away if you experience any serious side effects, such as: a fast heartbeat, muscle cramps/weakness, feeling very thirsty or needing to urinate often, joint pain."

Answered by AI

Is Striverdi respimat a corticosteroid?

"These events include asthma-related deaths.

If you use a long-acting beta2-adrenergic agonist like STRIVERDI RESPIMAT for your asthma, you're more likely to have an asthma-related event like asthma-related death."

Answered by AI

What is Striverdi respimat used for?

"Striverdi Respimat is an inhalation device that is used to manage chronic obstructive pulmonary disease (COPD) once per day. COPD is a long-term condition that necessitates use of this device every day to keep the symptoms at bay."

Answered by AI

Clinical Trials for Striverdi Respimat

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Striverdi Respimat clinical trials? We made a collection of clinical trials featuring Striverdi Respimat, we think they might fit your search criteria.Go to Trials
Image of University of Massachusetts Chan Medical School in Worcester, United States.

Paramedic Evaluation for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Worcester, MA
Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly. Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital. In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.
Recruiting
Has No Placebo
University of Massachusetts Chan Medical SchoolLaurel O'Connor, MD, MSc
Have you considered Striverdi Respimat clinical trials? We made a collection of clinical trials featuring Striverdi Respimat, we think they might fit your search criteria.Go to Trials
Image of Duke Asthma Allergy and Airway Center in Durham, United States.

Inhaled Treprostinil for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Durham, NC
The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.
Phase 2
Recruiting
Duke Asthma Allergy and Airway CenterUnited Therapeutics
Image of Duke University Hospital in Durham, United States.

Photon-counting CT for Chronic Obstructive Pulmonary Disease

Any Age
All Sexes
Durham, NC
Purpose and objective: This project aims to evaluate photon-counting computed tomography (PCCT) quantitative accuracy using COPDGene subjects. The goal is to establish acquisition protocols for PCCT scans with proper post-processing (e.g., reconstruction parameters and harmonization techniques) that enable reproducible measurements of emphysema metrics (e.g., Perc15, LAA-950, HU accuracy) and airways (Pi10, WA%) in the lungs. Study activities and population group: The study will recruit subjects from a current study at Duke (COPDGene Phase 4, Pro00113442). Here are the aims: * The research team will request consent from participants to acquire PCCT scans at their Phase 4 COPDGene visit. Scans will be performed using a PCCT-specific protocol. * Reconstruct the PCCT images with multiple post-acquisition parameter settings. Apply harmonization techniques that are recently developed by the investigators of this study. Data analysis: * Identify the reconstruction and harmonization conditions that enable reproducible measurements of emphysema metrics (perc15, LAA-950, HU accuracy) and airways (Pi10, WA%), when compared to the counterpart EICT scans. * Demonstrate the non-inferiority and potentially improved capabilities of PCCT scans in cross-sectional and longitudinal studies. Risk/safety issues: The participants are asked to get an additional CT scan with a PCCT scanner at their COPDGene Phase 4 visit. This additional CT scan will be done using an inspiratory chest protocol with a total of 3 mGy (\~1.5 mSv) radiation dose. This is roughly equivalent of 6 month of background radiation. Women who are pregnant will not have a chest CT scan done until they are confirmed to be not pregnant.
Recruiting
Has No Placebo
Duke University HospitalEhsan Abadi, Ph.D.
Have you considered Striverdi Respimat clinical trials? We made a collection of clinical trials featuring Striverdi Respimat, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security